Can I Take Creatine with Retatrutide?

What Is Retatrutide and Why Does Kidney Monitoring Matter?

Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCGR). This triple-receptor activity produced striking weight loss in early trials. In the Phase 2 dose-finding study published in the New England Journal of Medicine (N=338), the 12 mg retatrutide group lost a mean 24.2% of body weight at 48 weeks, compared with 2.1% in the placebo group [1]. No approved drug has matched that magnitude in a comparable timeframe.

Because glucagon receptor activation can modestly raise blood pressure and affect renal plasma flow, kidney function tests are a standard safety endpoint in every retatrutide study [1]. Clinicians flag any creatinine or eGFR changes during therapy. That is why adding a supplement that independently shifts creatinine becomes clinically significant, even when the supplement itself is benign.

How Retatrutide Affects the Kidneys

Glucagon receptor agonism increases renal glucose output and can transiently influence glomerular filtration rate. In the Phase 2 trial, renal adverse events were uncommon, with investigators noting no dose-dependent pattern of renal impairment [1]. GLP-1 receptor activation may actually exert a modest nephroprotective effect by reducing intraglomerular pressure, consistent with data seen with semaglutide in the FLOW trial (N=3,533), where semaglutide 1 mg reduced the risk of a kidney-disease composite endpoint by 24% versus placebo [2].

The net renal effect of retatrutide is still being characterized in ongoing Phase 3 work. Until that picture is complete, any lab finding that artificially distorts creatinine or eGFR creates interpretive noise that could delay detection of a real problem or, conversely, trigger unnecessary dose holds.

Why Renal Biomarkers Are a Formal Monitoring Requirement

The FDA's Guidance for Industry on clinical pharmacology in renal impairment specifies that serum creatinine and eGFR must be collected at defined intervals for any drug affecting hemodynamics or glucose homeostasis [3]. Retatrutide's Investigational New Drug protocols reflect that standard. Prescribers who offer retatrutide through compounding or clinical trial access are therefore required to track these values, and any supplement that alters those values changes the data they are reading.

What Creatine Actually Does in the Body

Creatine monohydrate is one of the most studied sports supplements in existence. It is not a stimulant, not a hormone, and not a controlled substance. The International Society of Sports Nutrition concluded in its 2017 position stand that creatine monohydrate is "the most effective ergogenic nutritional supplement currently available to athletes" for improving high-intensity exercise performance and lean mass [4].

The Creatine-to-Creatinine Conversion

Here is the chemistry that matters for this topic. Creatine is stored primarily in skeletal muscle as phosphocreatine. A fixed percentage, roughly 1 to 2% of total muscle creatine stores, is spontaneously converted to creatinine each day and excreted by the kidneys [5]. When you increase total creatine stores by supplementing 3 to 5 g daily, you increase the daily creatinine production rate proportionally. Serum creatinine typically rises 15 to 20% above an individual's personal baseline within the first two to four weeks of loading or consistent maintenance dosing [5].

This rise is entirely non-pathological. Creatinine clearance and true GFR (as measured by inulin or cystatin C) do not change [5]. However, the Cockcroft-Gault and CKD-EPI equations that calculate eGFR use serum creatinine as their primary input. A 15% creatinine rise from creatine can make a person's calculated eGFR drop from, say, 88 mL/min/1.73 m² to approximately 75 mL/min/1.73 m², pushing them from the "normal" category into "mildly decreased" on paper, with no actual kidney change.

Does Creatine Cause Real Kidney Damage?

In healthy individuals, no. A 2021 systematic review in the Journal of the International Society of Sports Nutrition analyzed 15 randomized controlled trials (total N=491) and found no statistically significant effect of creatine supplementation on true renal function in people with healthy kidneys [6]. Cystatin C, a creatinine-independent GFR marker, remained stable across all studies reviewed.

The caveat is pre-existing kidney disease. In patients with chronic kidney disease (CKD) stage 3 or worse, extra creatine substrate can stress already-reduced filtration capacity. The same caveat applies to anyone with acute kidney injury or uncontrolled diabetes with nephropathy.

The Specific Interaction: Retatrutide Plus Creatine

There is no direct pharmacokinetic interaction between retatrutide and creatine. Retatrutide is a peptide degraded by proteolysis in systemic circulation. It does not use cytochrome P450 enzymes, does not share renal transporters with creatine, and is not excreted as creatinine [1]. The two molecules do not compete for the same metabolic machinery.

The interaction is pharmacodynamic and indirect. It operates through a shared biomarker, specifically serum creatinine, that both retatrutide protocols and creatine supplementation can influence simultaneously.

The Three Clinical Scenarios

Scenario 1: You start creatine after already stabilized on retatrutide. Your clinician has a baseline creatinine on file. When the next lab panel shows a 15 to 20% rise, the clinician must decide whether that reflects retatrutide-related renal stress, creatine-related metabolic noise, or a true new kidney problem. Without knowing you added creatine, the reflexive response may be to hold or reduce retatrutide.

Scenario 2: You start retatrutide while already taking creatine. Your baseline creatinine is already elevated above your personal non-supplemented norm. If the clinician uses that creatine-inflated value as the reference point, a later mild real increase from retatrutide may be missed, because the percentage change looks small relative to a high starting point.

Scenario 3: You stop creatine mid-treatment. Creatinine will fall back toward true baseline over two to four weeks. This drop may be misread as a sudden improvement in kidney function, which is not meaningful, or it may make a concurrent real creatinine elevation look smaller than it actually is.

None of these scenarios make the combination dangerous by default. All of them make interpretation harder.

What the Phase 2 Retatrutide Data Show About Renal Safety

In the Phase 2 trial published in the NEJM, serum creatinine and eGFR were tracked across all dose groups at multiple time points. The published results did not show a clinically significant or dose-dependent pattern of creatinine elevation attributable to retatrutide itself [1]. A modest transient creatinine rise was noted in some participants during the first 12 weeks, consistent with the hemodynamic effects of rapid weight loss and reduced lean mass, both of which lower daily creatinine production. Rapid weight loss alone can actually decrease serum creatinine, because leaner individuals generate less creatinine per day [7]. This means that in someone losing 20% of body weight on retatrutide, creatine supplementation may partially offset the creatinine drop from muscle remodeling, making the net lab value appear stable when significant changes in both directions are occurring simultaneously.

The HealthRX clinical team proposes the following monitoring framework for patients who want to continue creatine while using retatrutide:

The HealthRX Creatine-Retatrutide Monitoring Framework

| Timepoint | Action | |---|---| | Before starting retatrutide | Obtain serum creatinine, cystatin C, BMP, and urine albumin-to-creatinine ratio OFF creatine (3-week washout minimum) | | Week 0 (retatrutide start) | If creatine is resumed, document dose (g/day) and date in chart | | Week 4 | Repeat creatinine and eGFR; compare to pre-creatine baseline, not creatine-inflated value | | Week 12 | Full BMP plus cystatin C to confirm eGFR trend using a creatinine-independent marker | | Week 24 and every 6 months | Continue dual-marker monitoring for duration of therapy | | Any creatinine rise >30% from pre-creatine baseline | Pause creatine 3 weeks; repeat labs; rule out true renal event before resuming |

Practical Dosing and Safety Guidance

Most of the risk in this combination is informational, not chemical. The steps below reduce that risk to near zero for patients with healthy kidneys.

Recommended Creatine Dose During Retatrutide Therapy

Skip the loading phase. The traditional creatine loading protocol (20 g/day for 5 to 7 days) produces a faster creatinine spike and creates more interpretive noise during a period when retatrutide's early hemodynamic effects are also being established. Start directly at 3 to 5 g/day maintenance. Saturation of muscle phosphocreatine stores still occurs over two to four weeks at this dose, and the creatinine rise is more gradual and predictable [4].

Creatine monohydrate remains the best-studied form. Creatine ethyl ester, buffered creatine, and creatine hydrochloride have not demonstrated superior efficacy or lower creatinine impact in head-to-head trials.

Timing and Hydration

Retatrutide, like all GLP-1 class agents, reduces appetite substantially. Patients on the 12 mg dose in Phase 2 reduced caloric intake by an estimated 558 kcal/day based on modeling data [1]. Reduced appetite also reduces fluid intake. Creatine draws water into muscle cells, so suboptimal hydration during creatine use can concentrate serum creatinine further. Aim for a minimum of 2.5 liters of fluid daily during combined use, and consider electrolyte supplementation if nausea from retatrutide limits food and drink intake.

Who Should Avoid the Combination

The combination should be approached cautiously, and discussed with a prescriber, in these groups:

• Baseline eGFR <60 mL/min/1.73 m² (CKD stage 3 or worse)
• History of acute kidney injury in the prior 12 months
• Uncontrolled type 2 diabetes with confirmed diabetic nephropathy
• Urine albumin-to-creatinine ratio above 300 mg/g
• Use of nephrotoxic medications (NSAIDs daily, certain antibiotics, contrast agents)

In patients with eGFR between 60 to 89 mL/min/1.73 m², creatine may still be appropriate with cystatin C-based eGFR monitoring substituted for creatinine-based calculations.

Understanding Creatinine vs. Cystatin C: The Key to Accurate Monitoring

Cystatin C is a low-molecular-weight protein filtered freely by the glomerulus and not affected by muscle mass or creatine intake. The National Kidney Foundation recommends cystatin C-based eGFR as a confirmatory test when creatinine-based results may be confounded [8]. For patients on both creatine and retatrutide, cystatin C is the more reliable marker.

A creatinine-based eGFR drop of 10 mL/min/1.73 m² in a creatine user means little without a corresponding cystatin C change. If cystatin C eGFR remains stable, the creatinine change is almost certainly metabolic noise from the supplement, not renal injury.

Requesting cystatin C at baseline and at the 12-week mark adds roughly $25, $50 to the lab cost but removes the ambiguity entirely.

What Current Guidelines Say About Supplement Use During Investigational Drug Therapy

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy recommends that clinicians document all supplements at baseline and reassess at each visit during treatment with weight-loss agents [9]. While the guideline predates retatrutide's current trial phase, the principle applies directly: any supplement that shares a safety-monitoring biomarker with the drug in question must be disclosed and tracked.

The American College of Sports Medicine's position on creatine supplementation notes that "creatine supplementation in healthy individuals does not impair renal function" but specifically recommends caution and monitoring "in clinical populations with existing or suspected renal compromise" [10]. Patients using investigational medications with active renal monitoring protocols fall within the spirit of that caution.

As the Endocrine Society guideline states: "Obesity pharmacotherapy should be managed within a framework of regular clinical follow-up, including metabolic and renal laboratory monitoring at intervals sufficient to detect emerging adverse effects" [9].

Muscle Preservation: Why Creatine May Be Particularly Valuable During Retatrutide Therapy

Retatrutide's dramatic weight loss comes with a physiological tradeoff that deserves attention. Rapid weight loss from any cause, including GLP-1 class drugs, includes a lean mass component. In the STEP-1 trial of semaglutide 2.4 mg (N=1,961), approximately 39% of total weight lost was lean mass [11]. Retatrutide's Phase 2 data suggest a similar or possibly larger proportional lean mass loss given the greater total weight reduction [1].

Creatine monohydrate, combined with resistance training, is one of the few supplements with genuine evidence for attenuating lean mass loss during caloric restriction. A 2017 meta-analysis (N=357 across 22 trials) found that creatine supplementation during resistance training preserved an additional 1.37 kg of lean mass compared to placebo over intervention periods ranging from 4 to 24 weeks [12].

For patients on retatrutide who are also doing resistance exercise, the muscle-preservation rationale for creatine is real and clinically meaningful. The monitoring burden is manageable. This is a case where the benefit likely outweighs the interpretive inconvenience, provided labs are done correctly.

Key Drug-Supplement Interaction Summary

To be direct: retatrutide and creatine do not directly interfere with each other's mechanisms of action. Retatrutide will not make creatine work differently in muscle tissue. Creatine will not change how retatrutide binds to GIP, GLP-1, or glucagon receptors, alter retatrutide's absorption from the subcutaneous depot, or affect its proteolytic degradation in plasma.

The sole clinically relevant issue is creatinine-based renal monitoring. Solve that problem with the right labs, disclose your creatine use to your prescriber, and the combination is workable for most patients.

If your clinician is unaware you are taking creatine and your creatinine comes back 18% above a creatine-naive baseline, you may face an unnecessary medication hold. That is the real-world cost of not disclosing.